Cancer predisposing BARD 1 mutations affect exon skipping and are associated with overexpression of specific BARD 1 isoforms

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Next-generation sequencing for the diagnosis of hereditary breast and ovarian cancer using genomic capture targeting multiple candidate genes

  2014cited by this paper
• DNA double-strand break repair genes and oxidative damage in brain metastasis of breast cancer.

  2014cited by this paper
• Alternative splicing in cancer: implications for biology and therapy

  2014cited by this paper
• Mutational analysis of BRCA1/2 in a group of 134 consecutive ovarian cancer patients. Novel and recurrent BRCA1/2 alterations detected by next generation sequencing

  2014cited by this paper
• Hereditary Breast Cancer: The Era of New Susceptibility Genes

  2013cited by this paper
• Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas

  2013cited by this paper
• The genetic landscape of high-risk neuroblastoma

  2013cited by this paper
• Expression of oncogenic BARD1 isoforms affects colon cancer progression and correlates with clinical outcome

  2012cited by this paper
• BARD1: An independent predictor of survival in non‐small cell lung cancer

  2012cited by this paper
• Common variation at BARD1 results in the expression of an oncogenic isoform that influences neuroblastoma susceptibility and oncogenicity.

  2012cited by this paper
• Cancer predisposing BARD1 mutations in breast–ovarian cancer families

  2011cited by this paper
• BRCT domains

  2011cited by this paper
• Cancer predisposing mutations in BRCT domains

  2011cited by this paper
• Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing

  2011cited by this paper
• BARD1 homozygous deletion, a possible alternative to BRCA1 mutation in basal breast cancer

  2010cited by this paper
• Cancer predisposing missense and protein truncating BARD1 mutations in non‐BRCA1 or BRCA2 breast cancer families

  2010cited by this paper
• Impact of RING and BRCT Domain Mutations on BRCA1 Protein Stability, Localization and Recruitment to DNA Damage

  2010cited by this paper
• Distinct roles of BARD1 isoforms in mitosis: full-length BARD1 mediates Aurora B degradation, cancer-associated BARD1beta scaffolds Aurora B and BRCA2.

  2009cited by this paper
• The biology of ovarian cancer: new opportunities for translation

  2009cited by this paper
• Crystal Structure of the BARD1 Ankyrin Repeat Domain and Its Functional Consequences*♦

  2008cited by this paper
• Potential and limitations in early diagnosis of ovarian cancer.

  2008cited by this paper
• High frequency of BRCA1/2 germline mutations in consecutive ovarian cancer patients in Poland.

  2008cited by this paper
• Oncogenic BARD1 isoforms expressed in gynecological cancers.

  2007cited by this paper
• Identification of BARD1 splice-isoforms involved in human trophoblast invasion.

  2007cited by this paper
• Ten genes for inherited breast cancer.

  2007cited by this paper
• Variants in the GH-IGF axis confer susceptibility to lung cancer.

  2006cited by this paper
• The BARD1 Cys557Ser Variant and Breast Cancer Risk in Iceland

  2006cited by this paper
• Ankyrin repeat: a unique motif mediating protein-protein interactions.

  2006cited by this paper
• BARD1 induces apoptosis by catalysing phosphorylation of p53 by DNA-damage response kinase

  2005cited by this paper
• Structural basis for phosphorylation-dependent signaling in the DNA-damage response.

  2005influential reference
• Cancer Statistics, 2005

  2005cited by this paper
• Splicing in action: assessing disease causing sequence changes

  2005cited by this paper
• Nuclear–cytoplasmic translocation of BARD1 is linked to its apoptotic activity

  2004cited by this paper
• One in 10 ovarian cancer patients carry germ line BRCA1 or BRCA2 mutations: results of a prospective study in Southern Sweden.

  2004cited by this paper
• BARD1 Expression During Spermatogenesis Is Associated with Apoptosis and Hormonally Regulated1

  2004cited by this paper
• Mutation screening of the BARD1 gene: evidence for involvement of the Cys557Ser allele in hereditary susceptibility to breast cancer

  2004cited by this paper
• Hereditary ovarian cancer in Poland.

  2004cited by this paper
• Population attributes affecting the prevalence of BRCA mutation carriers in epithelial ovarian cancer cases in israel.

  2003cited by this paper
• Loss of Bard1, the Heterodimeric Partner of the Brca1 Tumor Suppressor, Results in Early Embryonic Lethality and Chromosomal Instability

  2003cited by this paper
• Genetic analysis identifies putative tumor suppressor sites at 2q35–q36.1 and 2q36.3–q37.1 involved in cervical cancer progression

  2003cited by this paper
• The BRCA1/BARD1 heterodimer, a tumor suppressor complex with ubiquitin E3 ligase activity.

  2002cited by this paper
• Nomenclature for the description of human sequence variations

  2001cited by this paper
• Identification of BARD1 as mediator between proapoptotic stress and p53-dependent apoptosis.

  2001cited by this paper
• Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer.

  2001cited by this paper
• Prenatal diagnosis of sporadic neurofibromatosis type 1 (NF1) by RNA and DNA analysis of a splicing mutation

  1999cited by this paper
• Splicing defects in the ataxia-telangiectasia gene, ATM: underlying mutations and consequences.

  1999cited by this paper
• The ankyrin repeat: a diversity of interactions on a common structural framework.

  1999cited by this paper
• Mutations in the BRCA1-associated RING domain (BARD1) gene in primary breast, ovarian and uterine cancers.

  1998cited by this paper
• Frequency of germline and somatic BRCA1 mutations in ovarian cancer.

  1998cited by this paper
• In Vitro Repression of Brca1-associated RING Domain Gene, Bard1, Induces Phenotypic Changes in Mammary Epithelial Cells

  1998cited by this paper
• Identification of a RING protein that can interact in vivo with the BRCA1 gene product

  1996cited by this paper

• Association Between Germline Mutations in BRF1, a Subunit of the RNA Polymerase III Transcription Complex, and Hereditary Colorectal Cancer.

  2018cites this paper